BCM
NMTR

BlueCrest Capital Management’s 9 Meters Biopharma NMTR Stock Holding History

BlueCrest Capital Management’s Portfolio NMTR Stock Details NMTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-575
Closed -$315K – 1919
2018
Q1 		$315K Buy
+575
New +$112K 0.01% 1021

Other funds holding NMTR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

BlueCrest Capital Management's NMTR Position: Q2 2018 in Review

BlueCrest Capital Management sold out of 9 Meters Biopharma (NMTR) in Q2 2018, closing a stake of 575 shares — an estimated $315K sold.

BlueCrest Capital Management first reported a position in NMTR in Q1 2018 and held it in 1 quarter. The position peaked at $315K in Q1 2018. 36 funds tracked by Wall St. Rank hold NMTR as of Q2 2018.

  • BlueCrest Capital Management reported no remaining 9 Meters Biopharma position as of Q2 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 575 9 Meters Biopharma shares in Q2 2018, an estimated $315K.
  • BlueCrest Capital Management first reported a position in 9 Meters Biopharma in Q1 2018 and held it in 1 quarter.
  • BlueCrest Capital Management's 9 Meters Biopharma position peaked at $315K in Q1 2018.
  • 36 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q2 2018.

Based on BlueCrest Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.